Information Provided By:
Fly News Breaks for February 9, 2020
Feb 9, 2020 | 17:39 EDT
Piper Sandler analyst Joseph Catanzaro raised his price target for Ocular Therapeutix to $7 from $5.50, while keeping an Overweight rating on the shares. The analyst notes that the company presented updated Phase I data for OTX-TIC, the intracameral travoprost insert for IOP-lowering in glaucoma, and the data continues to look favorable.
News For OCUL From the Last 2 Days
There are no results for your query OCUL